
Nextcure (NXTC) Stock Forecast & Price Target
Nextcure (NXTC) Analyst Ratings
Bulls say
NextCure Inc. shows a promising financial outlook based on its innovative immunomedicine pipeline, particularly the potential of LNCB74, which has demonstrated superior efficacy in preclinical trials compared to similar constructs, thereby positioning the company favorably within a competitive landscape. Additionally, NC605's encouraging preclinical results in chronic bone diseases and NC181's robust efficacy in Alzheimer's disease highlight the diversification of the company's portfolio, with ongoing patient enrollment signaling positive safety trends. The absence of standard of care in certain cancers and the potential for LNCB74 to significantly improve outcomes in challenging therapeutic areas enhances the overall value proposition for NextCure's stock moving forward.
Bears say
NextCure Inc's outlook is negatively impacted by the recent discontinuation of Pfizer's B7-H4 ADC program, SGN-B7H4V, which raises concerns about the viability of NextCure's own B7-H4-targeting therapy, LNCB74. Additionally, the company's operating expenses in the fourth quarter of 2024 exceeded expectations, contributing to a reduction in projected valuation from $4 to $3. These factors, coupled with the inherent risks of developing clinical-stage biopharmaceuticals, contribute to a cautious perspective on NextCure's financial future.
This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.
Nextcure (NXTC) Analyst Forecast & Price Prediction
Start investing in Nextcure (NXTC)
Order type
Buy in
Order amount
Est. shares
0 shares